Noon — 1:30 p.m.

Avoiding Medical Morbidities in the Pathway of Care for Schizophrenia

Chair: Henry A. Nasrallah, M.D.

Supported by AstraZenca Pharmaceuticals

6:30 p.m. — 9:30 p.m.

Raising Expectations in Schizophrenia: Enhancing Long-Term Outcomes

Chair: Daniel E. Casey, M.D.

Supported by Pfizer Inc.

Noon — 1:30 p.m.

Reconceptualizing Bipolar Disorder in 2001

Chair: Robert M.A. Hirschfeld, M.D.

Supported by GlaxoSmithKline

Noon — 1:30 p.m.

Reality Check: Real World Considerations in the Treatment of Mood and Anxiety Disorders

Chair: Martin B. Keller, M.D.

Supported by Pfizer Inc.

6 p.m. — 9 p.m.

Controversy in Psychiatry: Solutions for Recovery and Wellness

Chair: Gerald A. Maguire, M.D.

Supported by Eli Lilly and Company

6:30 a.m. — 8 a.m.

Integrated Treatment of Bipolar Disorder

Chair: Frederick K. Goodwin, M.D.

Supported by GlaxoSmithKline

Noon — 1:30 p.m.

Therapeutic Challenges in Managing Depression and Anxiety

Chair: David V. Sheehan, M.D.

Supported by Wyeth-Ayerst Laboratories

Noon — 1:30 p.m.

Expanding Horizons: Cholinesterase Inhibition in Alzheimer’s Disease and Beyond

Chair: Pierre N. Tariot, M.D.

Supported by Easai Inc. and Pfizer Inc.

6 p.m. — 9 p.m.

Optimizing Psychosis Management: Treatment for the Future

Chair: Prakash S. Masand, M.D.

Supported by Janssen Pharmaceutica

6:30 a.m. — 8 a.m.

Schizophrenia: Evolving Therapeutic Concepts

Chair: Stephen R. Marder, M.D.

Supported by Bristol-Myers Squibb

Noon — 1:30 p.m.

Individualizing Management of Depressive Disorders

Chair: Norman Sussman, M.D.

Supported by Organon Inc.

6 p.m. — 9 p.m.

Cognition in Schizophrenia: Restoring Functions

Chair: Herbert Y. Meltzer, M.D.

Supported by Pfizer Inc.